GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Equity-to-Asset

PuraPharm (HKSE:01498) Equity-to-Asset : 0.16 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PuraPharm's Total Stockholders Equity for the quarter that ended in Dec. 2024 was HK$111.2 Mil. PuraPharm's Total Assets for the quarter that ended in Dec. 2024 was HK$715.7 Mil. Therefore, PuraPharm's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.16.

The historical rank and industry rank for PuraPharm's Equity-to-Asset or its related term are showing as below:

HKSE:01498' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16   Med: 0.35   Max: 0.67
Current: 0.16

During the past 11 years, the highest Equity to Asset Ratio of PuraPharm was 0.67. The lowest was 0.16. And the median was 0.35.

HKSE:01498's Equity-to-Asset is ranked worse than
87.88% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.61 vs HKSE:01498: 0.16

PuraPharm Equity-to-Asset Historical Data

The historical data trend for PuraPharm's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Equity-to-Asset Chart

PuraPharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.33 0.25 0.18 0.16

PuraPharm Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.23 0.18 0.17 0.16

Competitive Comparison of PuraPharm's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PuraPharm's Equity-to-Asset falls into.


;
;

PuraPharm Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PuraPharm's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=111.198/715.725
=0.16

PuraPharm's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=111.198/715.725
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm  (HKSE:01498) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PuraPharm Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PuraPharm's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines